Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants - in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. In 2014, Dr. Reddy Laboratories was listed among 1200 of India's most trusted brands according to the Brand Trust Report 2014, a study conducted by Trust Research Advisory, a brand analytics company.By 2007, Dr. Reddy's had seven FDA plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.In 2010, the family-controlled Dr Reddy's denied that it was in talks to sell its generics business in India to US pharmaceutical giant Pfizer, which had been suing the company for alleged patent infringement after Dr Reddy's announced that it intended to produce a generic version of atorvastatin, marketed by Pfizer as Lipitor, an anti-cholesterol medication. Reddy's was already linked to UK pharmaceuticals multinational Glaxo Smithkline. Dr.S.Dr. Dr.Dr.Dr.Dr. Dr.
On Oct 7 and 8, 2024, the US Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a workshop titled "Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products". Stakeholders from the FDA, industry, academia, and contract research organizations convened to discuss strategies for advancing risk assessment methodologies and regulatory frameworks for complex generic products. By assembling experts from various sectors, the workshop explored various available strategies for immunogenicity risk assessment, providing valuable insights to support the development and assessment of generic peptide and oligonucleotide drug products. The discussions fostered a deeper understanding of how these methodologies can inform regulatory decision-making and enhance the development of safer and more effective therapeutics.
The gut-brain-heart axis represents a dynamic interplay between the gut microbiota, cognitive function, and cardiovascular health, with profound implications for understanding and managing chronic diseases. In dysbiosis, a disruption in microbial balance contributes to neuro-inflammation, mood disorders, neurodegenerative diseases, and cardiovascular conditions such as atherosclerosis and hypertension. To date, researchers explored different mechanism through which gut microbial communities influence the activities of brain and heart. In order to understand these mechanisms summative, in this review, we focused on key communication pathways between microbiota-gut-brain-heart, such as vagus nerve, gut-derived metabolites, and systemic inflammation. Furthermore, the review discusses the bidirectional nature of these relationships, where cardiovascular and cognitive health mutually influence one another. Therapeutic interventions, including probiotics, dietary modifications, biotechnological approach and lifestyle changes are evaluated for their potential to modulate the gut-brain-heart axis and improve health outcomes. Despite significant advances, challenges remain in understanding the complex interactions within this axis. Future research directions emphasize personalized medicine approaches and the potential of microbiome-targeted therapies to revolutionize the prevention and treatment of cognitive and cardiovascular disorders.
Niraparib is a potent, orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, specifically targeting PARP-1 and PARP-2 to induce selective cytotoxicity in malignancies by disrupting DNA repair mechanisms. Given that the S-niraparib exhibits significantly higher pharmacological activity than the R-isomer, the development of a precise analytical technique to ensure enantiomeric purity is a critical requirement for pharmaceutical quality control. This study details the development and validation of a stability-indicating chiral high-performance liquid chromatography (HPLC) method for the quantitative assessment of enantiomeric purity content. Separation was successfully achieved using a Chiralpak AS-H 250 × 4.6 mm, 5 μm column under isocratic conditions with a mobile phase consisting of n-hexane, ethanol, methanol, and diethylamine in a 750:100:150:1.0 (v/v/v/v) ratio. The system was operated at a flow rate of 0.7 mL/min and a controlled column temperature of 40°C, with detection monitored via a UV/visible detector at 240 nm. The method was rigorously validated in accordance with ICH Q2(R2) guidelines, demonstrating specificity, accuracy, and precision. A resolution factor of greater than 2.0 was maintained between niraparib and its isomer. Analytical sensitivity was established through the determination of the limit of detection (LOD) and limit of quantitation (LOQ) using signal-to-noise ratios of 3 and 10, respectively, with a 1 mg/mL sample concentration and a 10 μL injection volume. Calibration curves proved linear over the studied range, confirming the method's reliability. The results indicate that this stability-indicating approach is highly effective for routine in-process quality control, batch release testing, and long-term stability monitoring of niraparib drug substances.
Objectives: The objective of the study is to evaluate the dermatological safety, tolerability, and hypoallergenic potential of Venusia Cleanser using the human repeat insult patch test (HRIPT). Materials and Methods: A single-center, evaluator-blinded HRIPT was conducted on 220 healthy adults aged 18–65 years, including participants with sensitive skin identified through the lactic acid sting test. The test product (1% diluted Venusia Cleanser) and a negative control (0.9% isotonic saline) were applied occlusively on the participant’s back in three phases: Induction (nine 24 h applications), rest (14 days), and challenge (single 24 h application). Skin reactions were assessed using the Draize scale during induction and the International Contact Dermatitis Research Group scale during challenge. Safety and sensitization potential were evaluated qualitatively. Results: Of 220 participants recruited, 218 participants completed the study. 36% ( n = 78) were confirmed to have sensitive skin. During the induction phase, the mean cumulative irritation score for Venusia Cleanser was 0.08, significantly below the threshold of 2.0, which defines non-irritant status according to Bureau of Indian Standards - Indian Standard 4011: 2018 Methods of Test for Safety Evaluation of Cosmetics (Third Revision) guidelines. Throughout the challenge phase, no strong positive or irritant reactions were observed at any time point. Only a few participants experienced transient, minor, doubtful reactions at 48 h, which resolved quickly without any lasting effects. No adverse events or safety concerns were reported during the entire study period. Conclusion: Venusia Cleanser demonstrated a non-irritant and hypoallergenic profile under HRIPT conditions, supporting its safe repeated use, including in individuals with sensitive skin. Being a single-center study, the findings may limit the generalizability of the results to broader and more diverse populations.
